該当箇所へ

Sanofi社、Genedata Biologicsを導入:
創薬スループットとプロセス効率を向上

Genedata Biologics will be implemented at multiple Sanofi R&D sites and departments to improve biologics discovery throughput and process efficiency

October 30, 2013
Basel, Switzerland

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Sanofi, a leading global healthcare company, has chosen Genedata Biologics™ as its data management platform for biologics screening activities. The first-in-class enterprise system will be used across different Sanofi research sites as a data management and workflow support platform to automate experimental data capture, increase experimental throughput, and facilitate data sharing throughout the biologics R&D process.

Out of the box, Genedata Biologics supports diverse biologics R&D processes. The platform enables fully automated, high-throughput biopharmaceutical discovery and development workflows and can directly interact with laboratory instruments and robotics equipment. By increasing experimental throughput, minimizing data handling errors, and ensuring consistently high data quality standards, Genedata Biologics significantly improves efficiency in the discovery and development of novel protein-based therapeutics.

“We are delighted that Sanofi, a leading innovator in the discovery of novel biopharmaceuticals, has selected our Genedata Biologics platform,” said Dr. Othmar Pfannes, CEO of Genedata. “Our collaboration with Sanofi will drive the development of Genedata Biologics as the platform of choice for the discovery of novel biopharmaceuticals.”


Our collaboration with Sanofi will drive the development of Genedata Biologics as the platform of choice for the discovery of novel biopharmaceuticals